# Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.

> **NIH NIH R01** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2022 · $1

## Abstract

PROJECT SUMMARY/ABSTRACT
There is an abundance of evidence demonstrating the importance of Fc-mediated effector function to the overall
activity of an antibody in vivo. However, the relative contribution of virus neutralization versus effector functions
to the antiviral effect of an antibody remains undefined. We have proposed a series of experiments that will
quantify the contributions of Fc-mediated effector functions to the overall activity of an antibody. The quantitative
experiments will be performed in the setting of antibody treatment of SHIV infection in rhesus macaques. These
fundamental questions in immunology have yet to be answered, and the resultant information promises to
provide important insights on how the two major properties (neutralization versus effector functions) of a vaccine-
induced IgG response combine forces to ward off the establishment of HIV infection.

## Key facts

- **NIH application ID:** 10489271
- **Project number:** 5R01AI145645-05
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** DAVID D HO
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1
- **Award type:** 5
- **Project period:** 2019-09-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10489271

## Citation

> US National Institutes of Health, RePORTER application 10489271, Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo. (5R01AI145645-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10489271. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*